A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Komatsu, Hirotake ^a,b   Tanji, Etsuko ^a   Sakata, Naoaki ^b   Aoki, Takeshi ^b   Motoi, Fuyuhiko ^b   Naitoh, Takeshi ^b   Katayose, Yu ^b   Egawa, Shinichi ^b   Unno, Michiaki ^b   Furukawa, Toru ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN; MUCIN 2; MUCIN 5AC; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GNAS GENE; HUMAN; HUMAN CELL; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MU5AC GENE; MUC2 GENE; PANCREAS CELL; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA, MUCINOUS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MUCINS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84896876454     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087875     Document Type: Article

References (38)

1. Hruban RH, Pitman MB, Klimstra DS (2007) Intraductal tumors. In: Silverberg SG, editor. Tumors of the pancreas. AFIP Atlas of Tumor Pathology. Washington, DC: American Registry of Pathology. pp. 75-103.
2. Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, et al. (2011) Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 60: 509-516.
3. Furukawa T, Kuboki Y, Tanji E, Yoshida S, Hatori T, et al. (2011) Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 1: 161.
4. Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, et al. (2011) Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Sci Transl Med 3: 92ra66.
5. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, et al. (2011) Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 108: 21188-21193.
6. Dhanasekaran DN (2006) Transducing the signals: a G protein takes a new identity. Sci STKE 2006: pe31.
7. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, et al. (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340: 692-696. (Pubitemid 19214389)
8. Kalfa N, Lumbroso S, Boulle N, Guiter J, Soustelle L, et al. (2006) Activating mutations of Gsalpha in kidney cancer. J Urol 176: 891-895. (Pubitemid 44142552)
9. Fragoso MC, Latronico AC, Carvalho FM, Zerbini MC, Marcondes JA, et al. (1998) Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 83: 2074-2078. (Pubitemid 28496339)
10. Yamada M, Sekine S, Ogawa R, Taniguchi H, Kushima R, et al. (2012) Frequent activating GNAS mutations in villous adenoma of the colorectum. J Pathol 228: 113-118.
11. Delaney D, Diss TC, Presneau N, Hing S, Berisha F, et al. (2009) GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Mod Pathol 22: 718-724.
12. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, et al. (1996) Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol 148: 1763-1770. (Pubitemid 26171674)
13. Kobari M, Hisano H, Matsuno S, Sato T, Kan M, et al. (1986) Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs. Tohoku J Exp Med 150: 231-248. (Pubitemid 17234977)
14. Sugiura H, Ishikura H, Omi M, Kaji M, Iwai K, et al. (1994) Lymphokine-activated killer cytotoxicity against pancreas adenocarcinoma cell lines and vascular endothelial cells. Pathol Int 44: 688-696. (Pubitemid 24279801)
15. Yunis AA, Arimura GK, Russin DJ (1977) Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19: 218-235.
16. Furukawa T, Tanji E, Kuboki Y, Hatori T, Yamamoto M, et al. (2012) Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells. Mol Cancer 11: 88.
17. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A (2003) Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 162: 1807-1815. (Pubitemid 36613039)
18. Kadota K, Nishiyama T, Shimizu K (2012) A normalization strategy for comparing tag count data. Algorithms Mol Biol 7: 5.
19. Raz T, Kapranov P, Lipson D, Letovsky S, Milos PM, et al. (2011) Protocol dependence of sequencing-based gene expression measurements. Plos One 6: e19287.
20. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210. (Pubitemid 34679544)
21. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, et al. (2013) NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 41: D991-995.
22. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M (2012) KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40: D109-114.
23. Yamanaka S, Sunamura M, Furukawa T, Sun L, Lefter LP, et al. (2004) Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis. Lab Invest 84: 1339-1351.
24. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632. (Pubitemid 28334795)
25. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
26. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, et al. (2002) Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 160: 1745-1754. (Pubitemid 34525654)
27. Song KS, Lee WJ, Chung KC, Koo JS, Yang EJ, et al. (2003) Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J Biol Chem 278: 23243-23250. (Pubitemid 36830137)
28. Chung WC, Ryu SH, Sun H, Zeldin DC, Koo JS (2009) CREB mediates prostaglandin F2alpha-induced MUC5AC overexpression. J Immunol 182: 2349-2356.
29. Kim YO, Jung MJ, Choi JK, Ahn do W, Song KS (2011) Peptidoglycan from Staphylococcus aureus increases MUC5AC gene expression via RSK1-CREB pathway in human airway epithelial cells. Mol Cells 32: 359-365.
30. Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9: 874-885.
31. Furukawa T, Kloppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, et al. (2005) Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 447: 794-799. (Pubitemid 41728866)
32. Basturk O, Khayyata S, Klimstra DS, Hruban RH, Zamboni G, et al. (2010) Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol 34: 364-370.
33. Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8: 3329-3341.
34. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Goto M (2010) Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Sci 17: 108-124.
35. Luttges J, Zamboni G, Longnecker D, Kloppel G (2001) The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 25: 942-948. (Pubitemid 32594989)
36. Wilson CH, McIntyre RE, Arends MJ, Adams DJ (2010) The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 29: 4567-4575.
37. Ideno N, Ohtsuka T, Kono H, Fujiwara K, Oda Y, et al. (2013) Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258: 141-151.
38. Katsuno Y, Ehata S, Yashiro M, Yanagihara K, Hirakawa K, et al. (2012) Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-beta. J Pathol 228: 391-404.